Coronavirus-Spike-Proteinvarianten
Anmelder: Shionogi & Co., Ltd, KOTAI Biotechnologies, Inc. 🇯🇵
Details
- Veröffentlichungs-Nr.
- EP4790065
- Anmeldetag
- 4. Oktober 2024
- Veröffentlichung
- 10. April 2025
- Rechtsraum
- EP
Abstract
Coronavirus spike protein variants for use in antigens for vaccines for coronavirus infection are provided.A coronavirus spike protein variant comprising:(a) a receptor binding domain (RBD) consisting of an amino acid sequence set forth in SEQ ID NO: 1;(b) an RBD consisting of an amino acid sequence obtained by substituting, deleting, inserting, or adding one to several amino acids in the amino acid sequence set forth in SEQ ID NO: 1, and having neutralizing antibody-inducing activity against SARS-CoV-2 and SARS-CoV-1 equivalent to that of an RBD consisting of the amino acid sequence set forth in SEQ ID NO: 1; or(c) an RBD consisting of an amino acid sequence that has at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 1, and having neutralizing antibody-inducing activity against SARS-CoV-2 and SARS-CoV-1 equivalent to that of the RBD consisting of the amino acid sequence set forth in SEQ ID NO: 1.
Anmelder
- Firmen
- Shionogi & Co., Ltd
KOTAI Biotechnologies, Inc. - Land
- 🇯🇵 Japan
Shionogi ist ein japanischer Pharmakonzern mit Schwerpunkt auf Arzneimittelentwicklung. Das Patentportfolio konzentriert sich auf Medizintechnik und Gesundheit sowie organische Chemie, ergänzt durch Pharma und Biotechnologie. Anmeldungen sind von 2000 bis in die Gegenwart belegt.
825 Patente in unserer Datenbank